« Return to News | Drug Sponsors

Sanofi collaborates with Rib-X Pharmaceuticals

Thursday, July 7, 2011 01:10 PM

Sanofi has signed a research collaboration with Rib-X Pharmaceuticals to investigate new types of antibiotics, according to InPharm.

Paris-based Sanofi has agreed to license Rib-X’s antibiotics in return for an upfront payment of $10 million and further milestones that could be worth more than $186 million per product developed.

The partners aim to produce treatments for multi-drug resistant bacteria, infections from which are responsible for at least 25,000 patient deaths in the European Union each year.

Elias Zerhouni, president of global research and development at Sanofi, said, "The clinical need for new antibiotics is reaching crisis level, yet the antibiotic pipeline is running dry and fewer and fewer companies are working to develop drugs in this space.”

Should Sanofi choose to exercise its option under the agreement, U.S.-based Rib-X could receive up to $86 million in development and regulatory milestones and over $100 million in commercial milestones payments on a per product basis.

Royalty rates on net sales could reach low double-digit figures, and Rib-X retains a co-promotion option in the U.S. on one of the molecules from the collaboration.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.